ClinicalTrials.gg
TerminatedNCT04013217Updated Apr 13, 2025

Evaluate Eribulin ORA in Subjects With Solid Tumors

A Phase 1 interventional study of Eribulin ORA in Solid Tumor, sponsored by Health Hope Pharma. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-13.

Sponsored by Health Hope Pharma · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor Decision

From the registry’s dates

  • Primary completion was Mar 2022, 4 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a nonrandomized, open-label, dosed escalation, safety activity, and PK study to determine the MTD and optimal dosing regimen of Eribulin ORA.

Read the detailed description

This is a multicenter, open-label safety, tolerability, pharmacokinetic, and activity study. Eligible subjects will be adults with advanced solid tumors.

Groups of 3 to 6 subjects will receive a single dose of Eribulin ORA on Day 1 and Day 8 of a 21 day cycle and will be followed for toxicity. If non linearity in PK is observed, additional subjects will be added with study drug administered on Day 1 and 8 once every three weeks cycle. Subjects who tolerate the study drug and have stable disease or better response will be eligible to receive ongoing treatment.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Health Hope Pharma is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand and sign an form (ICF)
  2. Male and female adults, ≥18 years of age
  3. or cytologically confirmed solid tumor that is or unresectable and for which standard curative or palliative measures do not exist or are no longer effective; subjects enrolling in the dose expansion cohort must have breast cancer or liposarcoma.
  4. Must have at least one measurable site of disease as defined as per v1.1 criteria (dose expansion) or evaluable disease (dose escalation only)
  5. (ECOG)2 Performance Status ≤1
  6. Adequate hematologic status as demonstrated by not requiring transfusion support or granulocyte-colony stimulating factor (G-CSF) to maintain:

    • (ANC) ≥1.5 x 109/L
    • count ≥100 x 109/L
    • ≥9.0 g/dL
  7. Adequate liver function as demonstrated by:

    • Total and direct within normal range
    • (AST) and alanine aminotransferase (ALT) ≤3 (ULN)
    • Gamma-glutamyl transferase (GGT) ≤5 x ULN
    • Alkaline phosphatase ≤3 x ULN or ≤5 x ULN if bone or liver metastasis is present
  8. Serum creatinine ≤1.5 x ULN, or estimated ≥50 mL/min according to the Cockcroft-Gault equation
  9. (PT)/international normalized ratio (INR)/partial thromboplastin time (PTT) ≤1.5 x ULN OR if a subject is receiving anticoagulant therapy and PT or PTT is within therapeutic range of intended use of coagulants for 7 days prior to receiving study treatment
  10. Subjects receiving warfarin who are otherwise eligible and who may be appropriately managed with low molecular weight heparin, in the opinion of the Investigator, may be enrolled in the study provided they are switched to low molecular weight heparin at least 7 days prior to receiving study treatment.
  11. Willing and able to comply with scheduled visits, treatment plan and laboratory tests
  12. No concurrent except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder
  13. Men who are sterile (including vasectomy confirmed by post vasectomy semen analysis) OR agree to use a condom with spermicide and to not donate sperm during the study and for at least 90 days following last dose of Eribulin ORA
  14. Female subjects must be (>12 months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or must be using highly effective (ie, oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for 90 days after their last dose of assigned study treatment.
  15. Subjects who are of must have a negative serum pregnancy test at Screening and within 72 hours before the first dose.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have received recent anti-cancer therapy defined by:

    • Chemotherapy, immunotherapy, hormonal therapy and monoclonal antibodies (but excluding nitrosurea, mitomycin-C, targeted therapy) ≤28 days prior to starting study drug, or who have not recovered from side effects of such therapy to Grade 1. Subjects receiving luteinizing hormone-releasing hormone (LHRH) agonists may be considered for enrollment after discussion with the Sponsor.
    • Last administration of nitrosurea or mitomycin-C ≤42 days prior to starting study drug, or who have not recovered from the side effects of such therapy to Grade 1
    • Targeted therapy (eg, sunitinib, sorafenib, pazopanib) ≤14 days prior to starting study drug, or who have not recovered from the side effects of such therapy to Grade 1; or
    • Radiotherapy ≤28 days prior to starting study drug, or ≤14 days prior to starting study drug in the case of localized radiotherapy (eg, for analgesic purpose or for lytic lesions at risk of fracture), or who have not recovered from radiotherapy toxicities to Grade 1.
  2. Subject who have impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drugs (including gastric bypass surgery and total gastrectomy).
  3. Subjects who have undergone major surgery (eg, intra-thoracic, intra-abdominal or intrapelvic), open or significant traumatic injury ≤28 days prior to starting study treatment, or subjects who have had minor procedures, percutaneous biopsies or placement of vascular access device ≤7 days prior to starting study drug, or who have not recovered from side effects of such procedure or injury
  4. Subjects with congenital long syndrome
  5. Uncontrolled concurrent illness, including but not limited to ongoing or active serious infection requiring systemic antimicrobials (within 14 days prior to first dose), uncontrolled arterial hypertension (>160/100 mm/Hg on antihypertensive medications), chronic pulmonary disease requiring oxygen, known bleeding disorders, uncontrolled endocrine diseases, altered mental status or psychiatric illness/social situations that would limit compliance with protocol requirements.
  6. Known or suspected diagnosis of (HIV) or chronic active or C, or cirrhosis.
  7. Symptomatic or uncontrolled requiring current treatment (less than 28 days from last cranial radiation or 28 days from last use).
  8. Impaired cardiac function or cardiac disease including the following:

    • Clinically significant arrhythmias (except chronic well controlled atrial fibrillation)
    • (NYHA) Class III or IV congestive heart failure
    • Unstable angina pectoris within the last 6 months
    • Myocardial infarction within the last 6 months
  9. Subjects with a healing or open wound
  10. Lack of recovery of prior AEs to Grade ≤1 severity (National Cancer Institute [NCI] [CTCAE] v4.03)3 (except alopecia or lymphopenia) due to medications administered prior to the first dose of the trial drugs.
  11. Any other condition or finding (including social situation) that in the opinion of the Investigator may render the patient at excessive risk for treatment complications or may not be able to provide evaluable outcome information.
  12. Pregnant or breast-feeding women
  13. Known allergy to any of the formulation components of Eribulin ORA
  14. Currently taking following prohibited concomitant medication:

    • Strong cytochrome P450 (CYP) 3A4 inducer (eg, rifampin or St. John's Wort) or a strong inhibitor (eg, ketoconazole) within 14 days prior to treatment administration
    • Medication known to be strong P-gp inhibitors or inducers. Subjects who are taking such medications but who are otherwise eligible may be enrolled if they discontinue the medication 7 days before dosing and remain off that medication during treatment with Eribulin ORA.
    • An oral medication with a narrow therapeutic index known to be a P-gp substrate (eg, digoxin, dabigatran, colchicine) within 1 day prior to start of Eribulin ORA dosing in the study
    • Drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Eribulin ORA

    To determine the MTD of Eribulin ORA (oral eribulin mesylate and HM30181A) when administered on Day 1 and Day 8 of a 3 weeks cycle.

    Combination Product: Eribulin ORA

Interventions

  • Combination productEribulin ORA

    Oral eribulin mesylate will be supplied as an aqueous solution and HM30181A-UK

06

What researchers measure

Primary outcomes

  1. Dose Escalation: Maximum Tolerated Dose

    Occurrence of Dose-limiting toxicity (DLT) in all patients who received at lest one dose of Eribulin ORA.

    Time frame: 3 weeks

  2. Dose Expansion: Occurrence of Grade 3 and 4 treatment-related adverse

    Evaluate the occurrence of Grade 3 and 4 treatment-related adverse events to assess the safety of Eribulin IV or Eribulin ORA.

    Time frame: 6 weeks

Secondary outcomes

  1. Dose Escalation: Safety

    Occurrence of adverse events in all patients who signed the informed consent .

    Time frame: Up to 24 months

  2. Dose Escalation: Bioavailability

    Pharmacokinetic analysis of Area Under the Curve (AUC), Time to Maximum Effect (Tmax), and Peak Plasma Concentration (Cmax) will be done to determine bioavailability of Eribulin IV or Eribulin Ora in all patients who received at least one dose of Eribulin ORA.

    Time frame: Up to 24 months

  3. Dose Escalation: Tumor Response

    Evaluate objective tumor response rate for confirmed Partial, Stable, Complete Response, or Progression Disease in all patients who receive at lease one dose of Eribulin IV or Eribulin ORA.

    Time frame: up to 24 months

07

Study locations

1 site
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Mar 2022, 31 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2019
First posted
Jul 9, 2019
StartActual
Jul 29, 2019
Primary completionActual
Mar 2, 2022
CompletionActual
Mar 2, 2022
Last update
Apr 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04013217
Lead sponsor
Health Hope Pharma
Responsible party
Sponsor
First posted
Jul 9, 2019
Start date
Jul 29, 2019
Primary completion
Mar 2, 2022
Completion
Mar 2, 2022
Last update
Apr 13, 2025

Study contacts

David Cutler, MD
study director · Health Hope Pharma

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion